sluit venster

Log in

Gebruikersnaam Wachtwoord Gebruikersnaam en/of wachtwoord vergeten? Gebruikersnaam en wachtwoord aanvragen

Zoek in de HOVON website

Let op!
Mogelijk ziet u niet alle beschikbare info op deze pagina, omdat u niet bent ingelogd, of omdat u niet de juiste privileges heeft.

Clinical picture: NHL (Non Hodgkin Lymphoma)

Trial: HOVON 48 NHL / NHLFIT


News
1. Overview
2. Patient eligibility criteria
3. Registration (& randomization) of patients
4. Participating parties
5. Participating sites
6. Instruction videos
7. Download documentation / forms


return to top

News


No news


1. Overview



Summary

Efficacy and safety of subsequent treatment with 90Y-ibritumomab tiuxetan versus no further treatment in patients with stage III or IV follicular non-Hodgkin?s lymphoma having achieved partial or complete remission after first line chemotherapy. A prospective, multicenter, randomized phase III clinical trial


Status

closed


Members

The HOVON 48 NHL study is executed by Schering AG. For more information please contact:
Dr. M.H.J. van Oers AMC Amsterdam
(studiecoordinator for the Netherlands)
Prof. Dr. A. Hagenbeek UMCU Utrecht
(studiecoordinator)



Type of study

Prospective randomized Phase III study


Date of activation

09-Aug-2001


Date closed

20-Jan-2005


2. Patient eligibility criteria



3. Registration (& randomization) of patients



Registration

Central registration at the HOVON Data Center:
Erasmus MC Cancer Institute, Clinical Trial Center (Hs-423)
P.O. Box 2040
NL-3000 CA Rotterdam
Phone number.: +31.10.7041560 (working days 9.00-17.00)
Fax number.....: +31.10.7041028
TOP address...: http://www.hdc.hovon.nl/top


4. Participating parties



Coordinating investigator(s)

Dr. M.H.J. van Oers AMC Amsterdam
(studiecoordinator for the Netherlands)
Prof. Dr. A. Hagenbeek UMCU Utrecht
(studiecoordinator)


5. Participating sites



6. Instruction videos



7. Download documentation / forms


 Protocol



return to top